Shared and Distinct Genetic Features in Human and Canine B-cell Lymphomas

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Mar 31

PMID 35359007

Authors

Krysta Mila Coyle

Tiana Hillman

Matthew Cheung

Bruno M Grande

Kevin R Bushell

Sarah E Arthur

Miguel Alcaide

Nicole Thomas

Kostiantyn Dreval

Stephanie Wong

Krishanna Campbell

Ryan D Morin

Affiliations

Soon will be listed here.

Citing Articles

What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.

Bedkowska D, Al-Ameri S, Wieczorek A, Bubak J, Miszczak M Cancers (Basel). 2025; 17(4).

PMID: 40002191 PMC: 11853190. DOI: 10.3390/cancers17040596.

Characterization of the genomic landscape of canine diffuse large B-cell lymphoma reveals recurrent H3K27M mutations linked to progression-free survival.

van der Heiden A, Pensch R, Agger S, Gardner H, Hendricks W, Zismann V Sci Rep. 2025; 15(1):4724.

PMID: 39922874 PMC: 11807134. DOI: 10.1038/s41598-025-89245-0.

Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.

Licenziato L, Mazzone E, Tarantelli C, Accornero P, Rinaldi A, Divari S Animals (Basel). 2024; 14(10).

PMID: 38791684 PMC: 11117341. DOI: 10.3390/ani14101466.

Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.

Cahill J, Smith L, Gottipati S, Torabi T, Graim K Annu Rev Biomed Data Sci. 2024; 7(1):107-129.

PMID: 38648188 PMC: 11343685. DOI: 10.1146/annurev-biodatasci-102423-111936.

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.

Thomas N, Dreval K, Gerhard D, Hilton L, Abramson J, Ambinder R Blood. 2022; 141(8):904-916.

PMID: 36201743 PMC: 10023728. DOI: 10.1182/blood.2022016534.

References

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Smith P, Waugh E, Crichton C, Jarrett R, Morris J . The prevalence and characterisation of TRAF3 and POT1 mutations in canine B-cell lymphoma. Vet J. 2020; 266:105575. DOI: 10.1016/j.tvjl.2020.105575. View

Harrington B, Gardner H, Izumi R, Hamdy A, Rothbaum W, Coombes K . Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS One. 2016; 11(7):e0159607. PMC: 4951150. DOI: 10.1371/journal.pone.0159607. View

Alcaide M, Rushton C, Morin R . Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries. Methods Mol Biol. 2019; 1956:383-435. DOI: 10.1007/978-1-4939-9151-8_20. View

Morin R, Arthur S, Hodson D . Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?. Br J Haematol. 2021; 196(4):814-829. DOI: 10.1111/bjh.17811. View

Elvers I, Turner-Maier J, Swofford R, Koltookian M, Johnson J, Stewart C . Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 2015; 25(11):1634-45. PMC: 4617960. DOI: 10.1101/gr.194449.115. View

Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H . Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23(10):2116-25. PMC: 424394. DOI: 10.1038/sj.emboj.7600217. View

Rowell J, McCarthy D, Alvarez C . Dog models of naturally occurring cancer. Trends Mol Med. 2011; 17(7):380-8. PMC: 3130881. DOI: 10.1016/j.molmed.2011.02.004. View

Venkataramanan S, Gadek M, Calviello L, Wilkins K, Floor S . DDX3X and DDX3Y are redundant in protein synthesis. RNA. 2021; 27(12):1577-1588. PMC: 8594478. DOI: 10.1261/rna.078926.121. View

10.

Modiano J, Breen M, Burnett R, Parker H, Inusah S, Thomas R . Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005; 65(13):5654-61. DOI: 10.1158/0008-5472.CAN-04-4613. View

11.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

12.

Bushell K, Kim Y, Chan F, Ben-Neriah S, Jenks A, Alcaide M . Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood. 2014; 125(6):999-1005. DOI: 10.1182/blood-2014-10-602714. View

13.

Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-80. PMC: 2919935. DOI: 10.1073/pnas.1004594107. View

14.

Kimmelman J, Nalbantoglu J . Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res. 2007; 67(10):4541-4. DOI: 10.1158/0008-5472.CAN-06-3792. View

15.

Nasir L, Devlin P, McKevitt T, Rutteman G, Argyle D . Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia. 2001; 3(4):351-9. PMC: 1505860. DOI: 10.1038/sj.neo.7900173. View

16.

Gong C, Krupka J, Gao J, Grigoropoulos N, Giotopoulos G, Asby R . Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021; 81(19):4059-4075.e11. DOI: 10.1016/j.molcel.2021.07.041. View

17.

Hansen K, Khanna C . Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer. 2004; 40(6):858-80. DOI: 10.1016/j.ejca.2003.11.031. View

18.

Zandvliet M . Canine lymphoma: a review. Vet Q. 2016; 36(2):76-104. DOI: 10.1080/01652176.2016.1152633. View

19.

Welcker M, Orian A, Jin J, Grim J, Grim J, Harper J . The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004; 101(24):9085-90. PMC: 428477. DOI: 10.1073/pnas.0402770101. View

20.

Valli V, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F . Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol. 2010; 48(1):198-211. DOI: 10.1177/0300985810379428. View